Atlantic Pharmaceuticals moves corporate offices to Raleigh, N.C.; Company relocates to thriving biotechnology center.RALEIGH, N.C.--(BW HealthWire)--March 12, 1997--Atlantic Pharmaceuticals Inc. (Nasdaq Small Cap:ATLC ATLC Arbitrary Transmission Line Calculator ATLC Atomic Trades and Labor Council ATLC Air Transport Label Catalog ATLC Advanced Technology Licensing Company ) announced today that it is moving their corporate offices to Raleigh, North Carolina For other uses of this name, see Raleigh. Raleigh (IPA: /ˈrɑli/, ral-ee) is the capital of the State of North Carolina and the county seat of Wake County. . The new offices are located on the Centennial Campus of North Carolina State University History
Atlantic Pharmaceuticals Inc. 1017 Main Campus Drive, Suite 3900 Raleigh, NC 27606 Phone: (919) 513-7020 -- effective 4/15/97. Atlantic may be reached at (415) 726-1327 in the interim. Fax: (919) 513-7021 -- effective 4/15/97. Atlantic may be reached at (415) 726-3647 in the interim. "I am pleased to report that each of our four technologies is advancing more rapidly than we originally envisioned," said J.D. Lindjord, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Atlantic, "therefore, we are moving to Raleigh where the research infrastructure provides us with a strong base to support our development plans and puts us in the heart of North Carolina's well established biotechnology industry. This move represents an important progression in our strategy to expedite development of our existing technologies and puts us in an ideal environment to pursue additional technologies." Atlantic Pharmaceuticals is a biopharmaceutical company developing pharmaceutical and biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. products for a variety of therapeutic areas. The Company's strategy, which differentiates their approach from most biotechnology firms, is to develop a diverse portfolio of promising and independent product candidates licensed from a variety of sources. Currently, Atlantic is developing novel technologies in antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). gene therapy, cataract cataract, in medicine, opacity of the lens of the eye, which impairs vision. In the young, cataracts are generally congenital or hereditary; later they are usually the result of degenerative changes brought on by aging or systemic disease (diabetes). removal, prevention of restenosis following coronary angioplasty angioplasty (ăn`jēōplăs'tē), any surgical repair of a blood vessel, especially balloon angioplasty or percutaneous transluminal coronary angioplasty, a treatment of coronary artery disease. , and anti-inflammatory/analgesic drugs. As with any company developing novel therapeutics, Atlantic may make certain forward-looking statements that relate to future business and financial performance. Such statements can only be predictions and the actual events or future results may differ from those discussed, due, among other things, to those risks described in the company's reports on forms 10-QSB and 10-KSB. For more information on Atlantic Pharmaceutical's technologies, visit the company's homepage at http://www.atlan.com. Atlantic's press releases are available through BusinessWire's web site at http://www.businesswire.com. The releases also are available at no charge through BusinessWire's fax-on-demand service at 888-286-8109. CONTACT: Lisa Wolford (212) 484-7058 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion